
CLYM Stock Forecast & Price Target
CLYM Analyst Ratings
Bulls say
Climb Bio is a promising biotech company with a strong pipeline and a focus on developing therapies for immune-mediated diseases. Their lead drug, Budoprutug, has shown positive results in non-human primate studies and we expect it to demonstrate similar results in its upcoming Phase 1 readout. Additionally, budo's potential dosing advantage over first-gen agents and upcoming data in primary membranous nephropathy (pMN) and immune thrombocytopenia (ITP) add to our positive outlook. With a positive safety profile and a strong cash runway, we see potential upside for Climb Bio's stock in the mid-$20s range should CLYM replicate NHP results and demonstrate a feasible extended dosing profile.
Bears say
Climb Bio is a clinical-stage biotechnology company with a potential negative outlook due to several factors. These include the potential competition from other companies with similar products, the regulatory challenges and potential delays in gaining approval, and the limited clinical data and small sample sizes for their pipeline products which may not accurately reflect their potential efficacy for treating immune-mediated diseases. Additionally, their stock has already had a significant increase this year and may face challenges in sustaining this growth without a steady stream of positive catalysts.
This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
CLYM Analyst Forecast & Price Prediction
Start investing in CLYM
Order type
Buy in
Order amount
Est. shares
0 shares